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Abstract
Surrogate end-points of cardiovascular disease can provide useful information in cross-
sectional, prospective and interventional studies. They provide information on association
with risk factors, natural history and factors associated with disease progression. Because
every participant can reach an end-point, sufficient power can be attained with much smaller
numbers of subjects in surrogate end-point studies than in studies that use clinical end-
points, so that the costs are likely to be substantially less. Measures of carotid intima–media
thickness (IMT) by B-mode ultrasonography and of coronary calcification by electron beam
computed tomography (EBCT) appear to be the most promising surrogate end-points.
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Introduction
Although cardiovascular disease is the commonest cause of
death in Western countries, the large number of cardiovas-
cular events result from a low absolute event rate in a large
number of people. Prospective trials that assess the effect
of an intervention on event rate therefore require large
numbers of subjects to be followed for many years, at huge
expense. This has led investigators to use surrogate end-
points. With the use of surrogate end-points, every partici-
pant can reach an end-point, which is usually a continuous
rather than a categorical variable. As a result, sufficient
power can be attained by studying much smaller numbers
of subjects for shorter periods of time. There are, however,
inherent problems with this approach. The validity of a surro-
gate end-point must be established. This in itself requires a
prospective study, adequately powered, to demonstrate that
the surrogate end-point is able to predict future cardiovas-
cular events. Furthermore, for a surrogate end-point to be
worthwhile, its ability to predict future cardiovascular events
must exceed that of conventional risk factors.
Surrogate end-points that have been used to assess the
risk of cardiovascular events, and to which this commen-
tary will be restricted, include the following: resting
12-lead electrocardiogram; coronary artery luminal diam-
eters assessed by coronary angiography; arterial stiff-
ness assessed directly, as change in luminal diameter
during the cardiac cycle adjusted for lumen diameter and
pulse pressure, or indirectly, as pulse wave velocity;
brachial artery flow-mediated dilatation; carotid and
femoral artery IMT; and coronary artery calcification
detected by EBCT.2
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Resting 12-lead electrocardiogram
One of the early surrogate end-points was the resting 12-
lead electrocardiogram. In the Honolulu heart programme
[1] both major and minor electrocardiogram abnormalities
were predictive of subsequent coronary heart disease
(CHD) events. Minnesota-coded ECG events were also
used in the 10-year follow up of the Bedford survey of car-
diovascular disease in relation to impaired glucose toler-
ance and diabetes [2]. However, minor electrocardiogram
abnormalities such as T-wave changes can be nonspe-
cific, and it can be difficult to demonstrate progression or
regression of CHD.
Coronary arteriography
There is a poor relationship between the severity of coro-
nary lesions and their likelihood to cause subsequent
cardiac events. Angiograms from patients before they
had had a myocardial infarction showed that the median
percentage stenosis at infarct-related lesions was only
48%, and that only 22% of the infarct-related lesions
had a degree of stenosis greater than 70% [3]. Coronary
artery luminal diameters assessed by coronary angiogra-
phy were used in the Familial Atherosclerosis Treatment
Study [4]. Men with coronary disease (n = 120) were
randomized to two different cholesterol-reducing treat-
ment regimens or placebo. Regression of disease was
more common in the treatment groups. Degrees of
stenoses were reduced by 0.3 and 1.1% in the treat-
ment groups, whereas there was a 2% increase in the
placebo group. Despite the small changes in angio-
graphic appearances, there was a 73% reduction in clin-
ical events in the treatment group compared with the
placebo group. Several other intervention studies have
used angiography as a surrogate marker for cardiovascu-
lar outcomes.
What has emerged is that the small angiographic changes
seen do not correlate with the marked reductions in car-
diovascular events. Thus, the relationship between degree
of stenosis and subsequent myocardial infarction and the
relationship of the relatively small changes seen during
intervention to the much larger effects on clinical events
do not suggest that coronary angiography is an ideal sur-
rogate end-point for cardiovascular intervention studies.
Brachial artery flow-mediated dilatation and
arterial stiffness
Data from an autopsy study [5] demonstrated that ather-
osclerotic involvement of vessels correlates with arterial
stiffness assessed noninvasively before death. An asso-
ciation between aortic stiffness and the degree of coro-
nary artery disease assessed at coronary angiography
has also been reported [6]. However, no prospective
studies assessing the ability of measurements of arterial
stiffness to predict future cardiovascular events have
been reported.
Brachial artery flow-mediated dilatation, or endothelium-
dependent dilatation, may be induced by reactive hyper-
aemia after vessel occlusion and release. Although
flow-mediated dilatation has been shown to be reduced in
groups known to be at high risk of CHD, such as individu-
als with familial hypercholesterolaemia [7] and diabetes
[8], its ability to predict future events has not been
assessed prospectively.
Arterial intima–media thickness assessed by
B-mode ultrasonography
With use of B-mode ultrasonography, the combined thick-
ness of the intima and media, the IMT, can be assessed.
The carotid and femoral arteries are most suitable for
study because of their superficial localization, size and
limited movement.
Increased common carotid IMT is associated with several
cardiovascular risk factors, including age, male sex, dia-
betes, total cholesterol and smoking. It also appears to be
an indicator for atherosclerosis in other arteries, including
coronary and lower limb [9].
In a prospective study in 1257 men [10] for each 0.1-mm
increase in IMT, the risk of acute myocardial infarction
increased by 11% (P < 0.001). Furthermore, carotid IMT
was measured in 5858 individuals who were 65 years of
age and older [11]; the relative risk of new myocardial
infarction or stroke for the quintile with the highest IMT as
compared with the lowest quintile was 3.87.
When carotid IMT was measured on the day of coronary
angiography, only a weak correlation was found between
coronary artery disease severity assessed angiographi-
cally and carotid IMT (r = 0.26;  P < 0.0001) [12]. This
may, however, reflect the inadequacy of coronary angio-
graphy, rather than that of carotid IMT, to predict cardio-
vascular events.
Although atherosclerosis predominantly affects the intima,
ultrasound imaging cannot discriminate between the
intima and the media of the vessel wall [13]. Therefore, in
diseases associated with medial thickening, changes in
IMT may be less representative of changes in cardiovascu-
lar risk. Glycation of extracellular matrix in diabetes may
increase medial thickness [14]. We found IMT to be a less
useful surrogate marker of CHD than the 12-lead electro-
cardiogram in an intervention study comparing bezafibrate
to placebo in type 2 diabetic persons [15].
If a plaque is located at the site of IMT measurement, the
plaque thickness is included in the IMT value. Some
studies have used categorical measures of wall status
instead of IMT. Belcaro et al [16] derived an arterial ultra-
sound score based on the wall appearance of both carotid
and both femoral arteries. In a prospective study, 20003
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asymptomatic men with normal serum lipids were followed
for 6 years. Arterial ultrasound score was strongly predic-
tive of subsequent cardiovascular events.
Several prospective studies with cholesterol-lowering
drugs have shown that reduction in low-density lipoprotein
(LDL)-cholesterol was associated with either reduction in
progression of IMT or regression of IMT, and associated
with reduced cardiovascular events in the treated groups
compare with placebo. The Cholesterol Lowering Athero-
sclerosis Study [17] was a randomized, placebo-con-
trolled angiographic study that tested colestipol-niacin
plus diet in nonsmoking men with previous coronary
bypass surgery. In this study a subset of 78 individuals
also had carotid ultrasound measurements. Drug-treated
subjects showed a significant progressive reduction in
carotid IMT at 2 and 4 years. In the Pravastatin Lipids and
Atherosclerosis in the Carotid Arteries II study [18], indi-
viduals with moderately elevated LDL-cholesterol, coro-
nary artery disease and early evidence of carotid arterial
disease measured ultrasonically were randomized to
receive placebo or pravastatin. Regression of carotid IMT
with reduction in both coronary and all-cause mortality
were found in the pravastatin group.
The Asymptomatic Carotid Artery Progression Study [19]
was a randomized, double-blind, placebo-controlled multi-
centre trial in asymptomatic individuals with early carotid
atherosclerosis and moderately elevated serum LDL-
cholesterol; 910 individuals were followed for at least
33 months to determine the effects of lovastatin and war-
farin on the progression of IMT. After 6 months, although
IMT continued to progress in the placebo group, there
was a progressive reduction in the lovastatin group. There
was also a significant reduction in the incidence of cardio-
vascular events in the lovastatin group.
In the Kuopio Atherosclerosis Prevention Study [20], 447
men (mean age 57 years, range 44–65 years) with LDL-
cholesterol greater than 4.25 mmol/l and total cholesterol
below 8.0 mmol/l were randomized to receive pravastatin
40 mg/day or placebo for 3 years. There was a significant
reduction in progression in the pravastatin group in the
carotid, but not in the femoral arteries. There were eight
fatal and nonfatal myocardial infarctions in the placebo
group, and three in the pravastatin group. There is there-
fore some evidence that reduction in carotid IMT is
accompanied by a reduction in cardiovascular events.
Coronary calcification detected by electron
beam computed tomography
EBCT enables high-resolution images of the heart to be
acquired in less than 100 ms. The rapid image acquisition
time virtually eliminates motion artifact related to cardiac
contraction. EBCT allows the detection, localization and
quantification of calcification in the coronary artery tree.
Methods have been developed to quantify accurately the
burden of calcification detected by EBCT. The method of
Agatston et al [21] has been the most widely used. Four
major studies have assessed the predictive value of EBCT
prospectively [22–25].
In a multicentre study [22], 491 symptomatic patients
were followed for 30 ± 13 months for the definitive end-
points of death and myocardial infarction; the ability of
coronary calcification scores to predict events was com-
pared with that of coronary angiography. Coronary calcifi-
cation scores, but not the number of angiographically
diseased vessels, significantly predicted the probability of
a CHD-related event occurring during follow up.
Secci et al [23] followed 326 high-risk adults who had
undergone EBCT for 32 ± 4 months. The combined defini-
tive end-points of death, myocardial infarction and revas-
cularization were at least three times as frequent in those
with coronary calcium scores above the median.
Arad et al [24] followed 1173 asymptomatic individuals
who had undergone EBCT for a mean of 19 months. They
demonstrated that a calcium (Agatston) score of more
than 100 yielded an odds ratio of more than 25, and a
score of more than 160 yielded an odds ratio of more than
34 for the prediction of death, nonfatal myocardial infarc-
tion and revascularization.
However, a study reported by Detrano et al [25] of 1196
asymptomatic high coronary risk subjects who underwent
risk-factor assessment and EBCT demonstrated that the
coronary calcification scores failed to provide predictive
power of cardiovascular events over and above risk factor
assessment alone. On the other hand, we assessed 223
asymptomatic men aged 45–64 years with plasma choles-
terol of 6.5 mmol/l or greater and demonstrated that more
than one-quarter of those who were predicted to be at
high-risk of cardiovascular events by conventional risk
factors had no significant coronary calcification detected
by EBCT [26].
One retrospective study [27] used the surrogate end-
point of coronary calcification detected by EBCT to
assess the effect of statins. The change in the calcium
score over 12–15 months in 105 individuals who had
received a statin was compared with the change in 44
subjects who had not received this treatment. A net
decrease in the calcium score was observed only in the
65 treated individuals whose final LDL-cholesterol con-
centrations were less than 3.10 mmol/l.
Conclusion
With the exception of the 12-lead electrocardiogram, the
surrogate end-points assess properties of vessel walls.
Cardiovascular events involve the coagulation pathway aswell as the vessel wall, so that there are obvious limita-
tions to the predictive powers of the surrogate end-points.
The two most promising surrogate end-points are estima-
tion of coronary calcification by EBCT and determination
of IMT in carotid and femoral arteries by ultrasonography.
It is unlikely that the use of surrogate markers for cardiovas-
cular disease could ever replace clinical end-point studies.
However, there are some clear benefits to the use of surro-
gate markers in studies of cardiovascular disease. They
provide information on the natural history and factors asso-
ciated with progression. In trials that use clinical end-
points, thousands of patients are usually needed to achieve
sufficient statistical power. Using surrogate end-points
every patient can provide an end-point and sufficient statis-
tical power can be achieved with much smaller numbers of
individuals. Smaller studies using surrogate markers can
provide preliminary information on the effectiveness of new
interventions and their mechanism of action.
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